A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
Study sponsor: Corcept Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-04-08Actual
Enrollment · participants152Actual
Source updated2025-07-16Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.